Cortexyme, Inc. (NASDAQ:CRTX) Insider Buys $232,028.00 in Stock

Cortexyme, Inc. (NASDAQ:CRTX) insider Epiq Capital Group, Llc acquired 8,600 shares of the business’s stock in a transaction on Friday, May 10th. The stock was acquired at an average cost of $26.98 per share, for a total transaction of $232,028.00. The purchase was disclosed in a document filed with the SEC, which can be accessed through this link.

Epiq Capital Group, Llc also recently made the following trade(s):

  • On Wednesday, August 21st, Epiq Capital Group, Llc acquired 4,965 shares of Cortexyme stock. The stock was acquired at an average cost of $25.35 per share, for a total transaction of $125,862.75.
  • On Monday, August 19th, Epiq Capital Group, Llc acquired 2,800 shares of Cortexyme stock. The stock was acquired at an average cost of $26.46 per share, for a total transaction of $74,088.00.

CRTX opened at $24.48 on Friday. Cortexyme, Inc. has a 12-month low of $19.50 and a 12-month high of $47.50. The stock’s fifty day moving average price is $34.79.

Several institutional investors and hedge funds have recently bought and sold shares of CRTX. JPMorgan Chase & Co. bought a new position in shares of Cortexyme during the 2nd quarter worth $78,000. Wells Fargo & Company MN bought a new position in shares of Cortexyme during the 2nd quarter worth $191,000. Bank of New York Mellon Corp bought a new position in shares of Cortexyme during the 2nd quarter worth $349,000. Landscape Capital Management L.L.C. bought a new position in shares of Cortexyme during the 2nd quarter worth $535,000. Finally, Northern Trust Corp bought a new position in shares of Cortexyme during the 2nd quarter worth $991,000. 1.17% of the stock is currently owned by institutional investors and hedge funds.

Several equities analysts have commented on CRTX shares. Bank of America started coverage on Cortexyme in a research report on Monday, June 3rd. They issued a “neutral” rating and a $28.00 price objective on the stock. JMP Securities started coverage on Cortexyme in a research report on Monday, June 3rd. They issued a “mkt outperform” rating and a $53.00 price objective on the stock. Zacks Investment Research raised Cortexyme from a “hold” rating to a “buy” rating and set a $33.00 price objective on the stock in a research report on Wednesday, August 14th. Credit Suisse Group started coverage on Cortexyme in a research report on Monday, June 3rd. They issued an “underperform” rating and a $14.00 price objective on the stock. Finally, Canaccord Genuity started coverage on Cortexyme in a research report on Monday, June 3rd. They issued a “buy” rating and a $42.00 price objective on the stock. One analyst has rated the stock with a sell rating, one has assigned a hold rating and two have issued a buy rating to the company. The company presently has a consensus rating of “Hold” and an average target price of $34.00.

About Cortexyme

Cortexyme, Inc, a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's disease and other degenerative disorders. Its lead drug candidate is COR388, an orally-administered brain-penetrating small molecule gingipain inhibitor, which has completed Phase 1a and Phase 1b clinical trials for use in patients with mild to moderate Alzheimer's disease.

Further Reading: Rule of 72

Receive News & Ratings for Cortexyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cortexyme and related companies with MarketBeat.com's FREE daily email newsletter.